ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Hawaii Gets CBCCP Award

August 12, 1977

How Low Can You Go? ODAC Accepts Retrospective Study for Accelerated Approval

September 30, 2011

Two Papers Evaluate CyberKnife Survival Rates and Tolerability

November 29, 2013

Preoperative Drug Combo Benefits HER-2 Breast Cancer

April 29, 2005

NCI “Rescues” 31 Grants From Other Institutes, Funds Them at 41.6 Million; Scores Were 148-270

August 9, 1974

NIH, NCI Being Discussions With HCFA On Reimbursement

April 26, 1996